PI5P4K 抑制剂:有前途的机遇和挑战
Koh Takeuchi1,2, Lisa Nagase3, Shun Kageyama4
1Graduate School of Pharmaceutical Sciences, The University of Tokyo, Bunkyo-ku, Japan.
The FEBS journal
|January 19, 2025
概括
酸丁醇5-酸4-激酶 (PI5P4K) 是关键的脂类激酶,参与癌症和免疫调节. 本综述分析了PI5P4K异酶和抑制剂,解决了针对性治疗治疗疗法开发的挑战.
科学领域:
- 生物化学 生物化学
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 酸丁醇5-酸盐4-酶 (PI5P4K) 是将PI5P转化为PI(4,5) P2.2.的酶.
- PI5P4K家族有三种哺乳动物异酶 (α,β,γ),它们使用GTP和ATP作为光.
- PI5P4Kβ独特地感知GTP水平,影响其激酶活性.
研究的目的:
- 提供PI5P4K异酶的不同作用的分析概述.
- 审查PI5P4K抑制剂的最新发展.
- 为应对PI5P4K抑制剂开发的挑战,并促进有针对性的治疗策略.
主要方法:
- 对PI5P4K异酶和抑制剂的现有文献的审查.
- 对PI5P4K抑制剂的结构性见解的分析.
- 讨论用于体内评估的药理动力学标记物识别.
主要成果:
- PI5P4Kα和β在瘤发生过程中至关重要;PI5P4Kγ调节免疫和神经系统.
- 药理学向PI5P4K为癌症,免疫功能障碍和神经退行性疾病提供了治疗潜力.
- 开发PI5P4K抑制剂的挑战包括因抑制剂设计和评估方法的疗效差异.
结论:
- 了解单个异酶作用是针对PI5P4K向治疗的关键.
- 克服抑制剂开发中的挑战需要解决ATP水平,非催化功能和药理动力学标记.
- 对结构洞察力和药理动力学标记物的进一步研究对于有效的PI5P4K向疗法至关重要.
关键词:
在PI3K中,PI3K是指PI3K.PI4P5K/PIPKI/I类型 PIPKK 的情况.PI5P4K/PIPKII/II类型的PIPKK.癌症 癌症 癌症 癌症 癌症药物开发是药物的发展.酸的含量是什么?脚手架的功能是一个脚手架的功能.更多相关视频
10:33Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
Published on: October 26, 2015
11.3K
08:49Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
Published on: January 22, 2019
9.1K
相关概念视频
01:23Dipeptidyl Peptidase 4 Inhibitors
165
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
165
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
464
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
464
02:04Protein-protein Interfaces
12.4K
Many proteins form complexes to carry out their functions, making protein-protein interactions (PPIs) essential for an organism's survival. Most PPIs are stabilized by numerous weak noncovalent chemical forces. The physical shape of the interfaces determines the way two proteins interact. Many globular proteins have closely-matching shapes on their surfaces, which form a large number of weak bonds. Additionally, many PPIs occur between two helices or between a surface cleft and a...
12.4K
02:34Inhibition of Cdk Activity
4.6K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K